

“Azadirachta Indica – A Double-Blind Randomized Placebo- Controlled Parallel Study Homoeopathic Pathogenetic Trial in accordance to the protocol given by Central Council of Research in Homeopathy.”

¹Dr. Anand Pal Singh Kushwah, ²Dr. Manisha P. Gajendragadkar, ³Dr.Komalba Zala

¹*Ph.D. Scholar, Department of Homeopathic Pharmacy, Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical College, Pune.*

² *Ph. D. Guide, Professor , Department of Homeopathic Pharmacy, Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical College, Pune.*

³ *Assistant Professor , Department of Obstetrics & Gynaecology, Kamdar Homoeopathic Medical College and Research Centre ,Rajkot.*

¹ *Email - Anandkushwah191@gmail.com,*
Contact Number:7974840780

KEYWORDS

ABSTRACT

RDBPC,epidemiologic,gold standard,HPT. Studies are ranked according to the quality of the evidence they can offer. In epidemiologic research, randomized double blind placebo control (RDBPC) trials are regarded as the "gold standard." Additionally, the same is covered in detail in this paper using an actual journal article as an example, using this study design to respond to "Does a once daily dose of Valacyclovir reduce the risk of transmission of genital herpes in a susceptible partner?" is the research question. The most compelling research design is still RDBPC studies, which use random assignment of the intervention to remove the impact of unknown or immeasurable confounding variables that could otherwise result in a skewed and inaccurate estimation of the treatment effect. I hope this is helpful. to novice researchers in order to comprehend causal hierarchy when assessing epidemiologic literature critically.

Background: “Azadirachta Indica – A Double-Blind Randomized Placebo-Controlled Parallel Study Homoeopathic Pathogenetic Trial in accordance to the protocol given by the Central Council of Research in Homeopathy.

1. INTRODUCTION

Homeopathic Pathogenetic Preliminary is a particular technique utilized in the homeopathic arrangement of medication to figure out the viability of another medication. It is finished by giving the new medication to a sound person called a "Prover" portion by portion to figure out the signs and side effects created by the Prover. It is a technique for recording the whole signs and side effects of another medication. The medication is to be demonstrated and won't have any demonstrated records of signs and side effects. Azadirachta Indica consumes portions of the plant for the vast majority restorative purposes like Anthelmintic, Against ulcer, Bronchitis, Asthma, Wound recuperating, Hostile to bacterial and different applications.

Causal Hierarchy: To ascertain if an exposure is directly accountable for a certain outcome, epidemiologists assess the available data. Research comes next. a ranking according to the caliber of the proof they are able to offer. The "Randomized Controlled Trial" (RCT) is the most robust study. In order to address the research question, "Does a once daily dose of Valacyclovir reduce the risk of transmission of genital herpes in susceptible partner?" the same is covered in detail in this paper using an example of an actual journal article that uses this study design. The research Heterosexual couples from 96 study sites who tested negative for HSV-2 infection were the population under investigation.[1] **The crucial terms are:**

Clinical studies:

Clinical trials are prospective investigations in which participants are given "something" at the researcher's choice and their results are monitored.

Using randomization:

The origins of contemporary statistics can be traced back to Sir Ronald Aylmer Fisher, who made contributions to comprehending randomization.

Controlled by a placebo:

Placebo controlled is another crucial term to comprehend. A placebo is a "inert" alternative, for an intervention or therapy. "Inert" refers to a compound's lack of recognized action that could influence the result.

Another name for blinding is masking:

This is yet another crucial term to comprehend. When it is possible for the result to be influenced by blindness is crucial when it comes to the expectations of the patient or researcher. There are three different forms of blinding: single blind, which occurs when the patient is blind, double blind, which occurs when both the patient and the researcher are blind, and triple blind.

Blind: when the investigator, patient, and data cleanup personnel are all blind.

2. LITERATURE REVIEW

A Systemic review of (51) journals - Including: (Journal name, Title of the article, Page no., ISSN no., Pharmacological action), published articles from various online portals.

3. OBJECTIVES / AIMS

- To Identify the effects of Azadirachta Indica on the Prover with the help of a day book.
- To analyse the symptoms observed after the compilation from the day book.

4. RESEARCH METHOD / METHODOLOGY

4.1 Research Design: This study employs an exploratory research design to evaluate the success of microfinance and PMMY.

4.2 Data Collection Method: Secondary data on PMMY will be collected from official reports, different publications of the Ministry of Finance, reports of the Reserve Bank of India, and the dataset from MUDRA. This will yield quantitative information on the overall loan disbursement, default rate, and demographic data of the borrowers.

4.3 Sampling Method: Convenience Random Sampling Method.

4.4 Study Design:

Double Blind Randomized, Placebo-controlled study, Parallel design.

4.5 Study Setting:

The study will be undertaken at Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical College, Pune.

4.6 Investigational Medicinal Products:

Azadirachta Indica is a medicine that has been used as a choice of drug for drug proving on Healthy provers.

4.7 Selection of Materials:

The Homoeopathic drug Azadirachta Indica will be purchased from G.M.P. approved Homoeopathic pharmacy (DR. Willmar Schwabe Pvt Ltd. Noida). A randomized, double- blind, placebo-controlled study was conducted at Bharati Vidyapeeth (Deemed to be University) Homoeopathic Medical College, Pune.

4.1 Route of administration:

Oral Route

4.8 Sample size:

40 Provers. Group 1 (placebo) and group 2 (Azadirachta indica). (25 Provers - Drugs, 09 Provers - Placebo, 06 provers - Dropout)

4.9 Sampling technique:

Simple Randomization Double Blind Placebo Control Trial.

4.10 Inclusion criteria:

1. Age: 18 - 60 years
2. Both guys and females
3. Healthy people with no obvious illness and typical unbiased.

4. Laboratory boundaries during screening Savvy to the point of recording cautiously current realities, abstract and objective Side effects created by the medication during demonstrating. Ready to be educated regarding the idea of the review and able to give Composed informed assent.

4.11 Exclusion criteria:

1. Any illness or condition which could think twice about hematopoietic, renal, endocrine, Aspiratory, focal sensory system, cardiovascular, immunological, dermatological, Gastrointestinal or some other body framework.
2. Persons with visual impairment. People who have gone through a medical procedure over the most recent two months. Arranged clinical/dental treatment during the demonstrating time frame including home grown or dietary enhancements, methods, or prescriptions that are probably going to disrupt, or considerably change, responsiveness to the demonstrating substance.
3. Volunteers on standard prescription (Allopathic, Ayurvedic, Homeopathic, Naturopathic, Unani, and so on) for any intense or persistent sickness.
4. Participants should not be on any homeopathic cure in the previous month and have had no massive change in wellbeing status somewhat recently.
5. Emotionally upset, crazy, or restless people. People having a known history of sensitivities, food touchiness, and so forth.
6. Women during pregnancy, puerperium, and keeping in mind that breastfeeding, and ladies who have gone through hysterectomy. No Terrible Hobbits.
7. Recent history of liquor abuse/chronic drug habits or improbable to forgo extreme liquor utilization/drug admission during the review time frame Cooperation in another clinical or demonstrating preliminary during the most recent a half year.

4.12 Data collection procedure:

- Screening of volunteers (form a)
- Written voluntary informed consent (form b part 1-2)
- Pre-medical examination trial P.M.E (Pre-Medical Examination)
- Post-medical examination trial P.M.E (Post-Medical Examination)
- Photographic record
- The Globules were medicated with medicine.
- Each prover was given a start date and a convenient daily contact time.
- For two weeks, the provers daily noted the typical condition in their daybook. This acted as an observation phase before to prove in order to create a baseline and personal control for each prover.
- When no new symptoms or indicators appeared after three weeks, the proving was said to have been over. After then, each person's daybooks were collected.
- The data thus obtained was analysed using the George Vithoulkas grading system.

5. DATA ANALYSIS:

Cumulative score of the Vithoulkas grading scale symptoms Grade Symptoms Table no.01

Symptoms	Grade
Difficulty in urine	6
Bodyache	5
Itching all over head	3
Dandruff on frontal region	3
Sleep satisfactory	2
Numbness	2
Feverish whole day	2

Table no.02

Particulars	Symptoms
-------------	----------

Mind	Prefer sound music, uncomfortable, Sluggishness, Drowsiness, want to be magnetised
Head	Itching all over the body, Dandruff, Itching of forehead
Eyes	Acrid, lacrimation
Nose	Sneezing
Mouth	Tongue ulcer
Stomach	stomach ache, Thirst for hot water, Desire for potato
Rectum	Mucus mixed stool, Increase urge for cough during diarrhoea
Urinary	Painful micturition
Cough	Cough with sticky sputum
Extremities	Leg-sided leg pain, Knee joint pain, Difficult to walk
Sleep	Sleep unsatisfactory
Fever	Tiredness, Feverish feeling
Skin	Itching all over the body

Potency 30C, Number of provers: 40

Researcher meetings – Daily bases.

After evaluation and study the drug picture of Azadirachta Indica was found.

6. CONCLUSION

Azadirachta Indica was identified for exploring its effects on human volunteers in a homoeopathic, potentized dose. The Potentization was carried out with documented force parameters. Further research on similar lines may help in Homoeopathic drug discovery. Further clinical trials and evaluations can enhance the strength of the current experiment and its outcome.

REFERENCES:

Paper/Article

1. Dubey S., Kashyap P. (2014). Azadirachta indica: a plant with versatile potential. *J Pharm Sci* 4: 39-46.
2. Pandey, G. Verma, K. K. Singh, M. (2014). Evaluation of phytochemical, antibacterial, and free radical scavenging properties of Azadirachta indica (neem) leaves. *Int J Pharm Pharm Sci* 6: 444-447.
3. Puri H.S. (1999). Neem: the divine tree Azadirachta indica. CRC Press.
4. Yadav D.K., Bharitkar Y.P., Chatterjee K., Ghosh M., Mondal N.B., Swarnakar S. (2016). Importance of neem leaf: An insight into its role in combating diseases
5. Uchegbu M., Okoli I., Esonu B., Iloeje, M. (2011). The growing importance of neem (Azadirachta indica A. Juss) in agriculture, industry, medicine, and Environment: A review. *Res J Med Plant* 5: 230-245.
6. Visvanathan R., Palanisamy P. T., Gothandapani L., Sreenarayanan V.V. (1996). Physical properties of neem nut. *J Agric Eng Res* 63: 19-25.
7. Bhowmik D., Chiranjib, Y.J., Tripathi K.K., Kumar K. S. (2010). Herbal remedies of Azadirachta indica and its medicinal application. *J Chem Pharm Res* 2: 62-72.
8. D.R. Judge, S.V. Patil and R. Purohit. Formulation of toothpaste from various forms and extracts of tender twigs of neem. *J Pharm Res*, 2008, 1(2): 148-152.
9. O. J. Uko, and T. N. Kamalu. The neem tree-uses and potentials. *Nig. J. Exptl. Applied Biol*, 2001, 2: 223-229.
10. N.E.S. Lale. Bio-activity and Limitation against wide spread use of neem products for the management of insect pests. *Niger. J. Appl. Biol*, 2002, 3:115-125.
11. I.P. Ogbuewu, V.U. Odoemenum, H.O. Obikaonu, M.N. Opara, O.O. Emenalom, M. Uchegbu, I. Okoli, B. Esonu, and M. Iloeje. The growing importance of neem (Azadirachta indica A. Juss) in agriculture, industry, medicine and Environment: A review. *Research Journal of Medicinal Plant*,

2011, 5(3):230-245.

12. K. Biswas, I. Chattopadhyay, R.K Banerjee and U. Bandyopadhyay. Biological activities and medicinal properties of neem (Azadirachta indica). Current Science-Bangalore-, 2002, 82(11): 1336-1345.

13. N. G. Hegde. Neem and small farmers-constraints at grass root level. Indian Forester, 1995, 121(11): 1040-1048.

14. M.A. Alzohairy. Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment. Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine, 2016,2016

15. R. Subapriya and S. Nagini. Medicinal properties of neem leaves: a review. Current Medicinal Chemistry-AntiCancer Agents, 2005, 5(2):149-156.

16. K. Girish and B.S. Shankara. Neem—a green treasure. Electronic journal of Biology, 2008, 4(3):102-111.

17. A. Akhila and K. Rani. Chemistry of the neem tree (Azadirachta indica A. Juss.). In *Fortschritte der Chemie organischer Naturstoffe/Progress in the Chemistry of Organic Natural Products*. Springer, Vienna, 1999, 78: 47-149

18. G.Brahmachari. Neem—an omnipotent plant: a retrospection. Chembiochem, 2004, 5(4): 408-421.

19. B.S. Siddiqui, F. Afshan, T. Gulzar, and M. Hanif. Tetracyclic triterpenoids from the leaves of Azadirachta indica. Phytochemistry, 2004, 65(16): 2363-2367.

20. U.P. Singh, S. Maurya and D.P. Singh. Phenolic acids in neem (Azadirachta indica) a major pre-existing secondary metabolites. Journal of herbal pharmacotherapy, 2005, 5(1):35-43.

21. I.P. Pandey, S.F. Ahmed, S. Chhimwal and S. Pandey. Chemical composition and wound healing activity of volatile oil of leaves of Azadirachta indica A. juss. Advances in Pure and Applied Chemistry, 2012, 1: 2167- 0854.

22. S.C. Gupta, S. Prasad, A.K. Tyagi, A.B. Kunnumakkara and B.B. Aggarwal. Neem (Azadirachta indica): An indian traditional panacea with modern molecular basis. Phytomedicine, 2017, 34: 14-20.

23. S.P. Dash, S. Dixit and S. Sahoo. Phytochemical and biochemical characterizations from leaf extracts from Azadirachta Indica: an important medicinal plant. Biochem Anal Biochem, 2017, 6(323): 2161-1009.

24. D.L. Jain, A.M. Baheti, S.R. Jain and K. R. Khandelwal. Use of medicinal plants among tribes in Satpuda region of Dhule and Jalgaon districts of Maharashtra—an ethnobotanical survey. Indian journal of Traditional knowledge, 2010, 9(1): 152-157

25. H.S. Puri. Neem: The Divine Tree Azadirachta indica, Harwood academic publishers, The Netherlands, 2003, p15.

27. B. Pokhrel, S. Rijal, S. Raut, and A. Pandeya. Investigations of antioxidant and antibacterial activity of leaf extracts of Azadirachta indica. African Journal of Biotechnology, 2015, 14(46): 3159-3163.

28. R. Paul, M. Prasad, and N.K. Sah. Anticancer biology of Azadirachta indica L (neem): a mini review. Cancer biology & therapy, 2011, 12(6):467-476.

29. R. Subapriya and S. Nagini. Ethanolic neem leaf extract protects against N-methyl-N'-nitro-Nnitrosoguanidine-induced gastric carcinogenesis in Wistar rats. Asian Pacific Journal of Cancer Prevention, 2003, 4(3): 215-224.

30. N.T. Nitire, A.A. Ansari and S.R. Naik. Anti-hyperglycemic activity of rutin in streptozotocin-induced diabetic rats: an effect mediated through cytokines, antioxidants and lipid biomarkers. Indian journal of experimental biology, 2014, 52:720 – 723

31. K. Sikdar, N. Das, S.B. Kesh and S. Dey. Quercetin and β -sitosterol prevent high fat diet induced dyslipidemia and hepatotoxicity in Swiss albino mice. Indian Journal of Experimental Biology, 2014, 52:60

32. A.K. Ghimeray, C.W. Jin, B.K. Ghimire and D.H.Cho. Antioxidant activity and quantitative estimation of azadirachtin and nimbin in Azadirachta Indica A. Juss grown in foothills of Nepal. African Journal of Biotechnology, 2009, 8(13): 3084-3091Chemical Science Review and Letters ISSN 2278-6783 DOI:10.37273/chesci.cs205205351 Chem Sci Rev Lett 2021, 10 (39), 396-401 Article

33. cs205205351 401

34. P. Maity, K. Biswas, I. Chattopadhyay, R.K. Banerjee and U. Bandyopadhyay. The use of neem for controlling gastric hyperacidity and ulcer. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*, 2009, 23(6): 747-755.

35. Koul, A., Goyal, R. and Bharati, S. Protective effect of *Azadirachta indica* A. Juss against doxorubicin-induced cardiac toxicity in tumour bearing mice. *Indian J Exp Biol*, 2014a, 52(4):323-31.

36. A. Koul, V. Mohan and S. Bharati. *Azadirachta indica* mitigates DMBA-induced hepatotoxicity: a biochemical and radiometric study. *Indian J Biochem Biophys*, 2014b, 51(1):37-45

37. P.K. Mukherjee, N.K. Nema, S. Bhadra, D. Mukherjee, F.C. Braga and M.G. Matsabisa. Immunomodulatory leads from medicinal plants. *Indian journal of traditional knowledge*, 2014, 13(2): 235-256

38. D. K. Yadav, Y. P. Bharitkar, K. Chatterjee, M. Ghosh, N. B. Mondal, and S. Swarnakar. Importance of Neem Leaf: An insight into its role in combating diseases. *Indian J Exp Biol*, 2016, 54(11):708-18.

39. U. Bandyopadhyay, K. Biswas, A. Sengupta, P. Moitra, P. Dutta, D. Sarkar, P. Debnath, C.K. Ganguly and R.K. Banerjee. Clinical studies on the effect of Neem (*Azadirachta indica*) bark extract on gastric secretion and gastroduodenal ulcer. *Life sciences*, 2004, 75(24): 2867-2878.

38. M.A. Subramanian and K.K. Lakshmanan, *Azadirachta indica* A. Juss. stem bark as an anti-leprosy source. In: Singh, R.P., Chari, M.S., Raheja, A.K., Kraus, W. (Eds.), *Neem and Environment*, Oxford & IBH Publishing Co. Pvt. Ltd., New Delhi, 1996, p1143 – 1150

40. 39. T. Fujiwara, E.Y. Sugishita, Y. Takeda, M. Shimizu, T. Nomura and Y. Tromita. Further studies on the

41. structures of polysachcharides from the bark of *Melia azadirachta*. *Chemical and Pharmacological Bulletin*, 1984, 32:1385 – 1391.

42. C. Devakumar and S. Sukhdev. In: Randhawa and Parmar, B.S., Eds., *Neem*, Society of Pesticide Science, New Delhi, 1996, p77-110.

43. U. Bandyopadhyay, R. Chatterjee, R.K. Bandyopadhyay, Process for the isolation of an active principle from *Azadirachta indica* useful for controlling gastric hyperacidity and gastric ulceration, US patent, 1998, 5730986.

44. U. Bandyopadhyay, K. Biswas, R. Chatterjee, D. Bandyopadhyay, I. Chattopadhyay, C.K. Ganguly, T. Chakraborty, K. Bhattacharyya, R.K. Banerjee. Gastroprotective effect of Neem (*Azadirachta indica*) bark extract: Possible involvement of H⁺ -K⁺ -ATPase inhibition and scavenging of hydroxyl radical. *Life Sciences*, 2002, 71: 2845 – 2865.

45. O.N. Nwali, A. Idoko, J.E. Okolie, E. Ezeh, P.O. Ugwudike, O.N. Rita, M.O. Ezenwali, I.A. Odo,

46. P.N. Ani and S.O. Okolie. Comparative analysis of the phytochemical compositions of leaf, stem-bark and root of *Azadirachta Indica* (neem). *Universal Journal of Pharmaceutical Research*, 2018, 3(5): 46-50.

47. K.P. Bhargava, M.B. Gupta, G.P. Gupta and C.R. Mitra. Anti-inflammatory activity of saponins and other natural products. *Indian Journal of Medical Research*, 1970, 58: 724-730.

48. P. Khosla, S. Bhanwra, J. Singh, S. Seth and R.K. Srivastava. A study of hypoglycaemic effects of *Azadirachta indica* (Neem) in normal and alloxan diabetic rabbits. *Indian Journal of Physiology and Pharmacology*, 2000, 44(1): 69-74.

Web References:

- https://www.mchemist.com/herboglo/_pdf/2%20neem.pdf

Full Home Address with Pin code / Zip code : (First Author) :-

Name :- Dr. Anand pal singh kushwah House Number :- 104,,

Apartment/Street/Building :- Trinetra appartment

Area/Nearby place :- City /Village/ Town :- 150feet ring road Rajkot. District :- Rajkot

State :- Gujarat Country :- India

Zip Code / Pin Code: 360006

Mobile Number with country code: +7974840780